Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer
NCT ID: NCT00524810
Last Updated: 2011-06-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
67 participants
INTERVENTIONAL
2004-02-29
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Caelyx - Taxotere
Pegylated liposomal doxorubicin
Caelyx 30 mg/m² day 1 every 3 weeks
Docetaxel
Taxotere 75 mg/m² day 2 every 3 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pegylated liposomal doxorubicin
Caelyx 30 mg/m² day 1 every 3 weeks
Docetaxel
Taxotere 75 mg/m² day 2 every 3 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* presence of measurable or bone lesion
* at least one lesion outside the radiated areas
* can have previously received hormonotherapy, chemotherapy in adjuvant phase, radiotherapy if older than 4 weeks
Exclusion Criteria
* symptomatic cerebral metastasis
* neuropathy \> NCI-CTC 2
* previous cancer within 10 years \_ previous cancer within 10 years
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ARCAGY/ GINECO GROUP
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ARCAGY-GINECO
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laure CHAUVENET, MD, PHD
Role: PRINCIPAL_INVESTIGATOR
Hôpital HOTEL DIEU - Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital HOTEL DIEU
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAPYTTOLE
Identifier Type: -
Identifier Source: org_study_id